Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-12-13Clinical Trial Update: A Novel fNIRS Neurofeedback Intervention for Enhancement of Working Memory in Attention Deficit Hyperactivity Disorder (ADHD) [NA]
A completed clinical trial evaluated a novel fNIRS neurofeedback intervention aimed at enhancing working memory in individuals with ADHD; re…
-
CLINICAL_TRIALS trial_result · 2023-12-12Clinical Trial Update: Process-instructed Self Neuro-Modulation (PRISM) for Attention Deficit/ Hyperactivity Disorder - Adults [NA]
Clinical trial update for PRISM self neuro-modulation in adults with Attention Deficit/Hyperactivity Disorder (ADHD); study completed with r…
-
CLINICAL_TRIALS trial_result · 2023-11-14Clinical Trial Update: Electroencephalogram (EEG) Study of Inattention Following Treatment With AKL-T01 [NA]
Completed EEG study update on AKL-T01 for attention in ADHD; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-11-02Clinical Trial Update: Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD [Phase 3]
Phase 3 trial update for amphetamine extended-release tablets in adults with ADHD; study completed with results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-10-26Clinical Trial Update: A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity [Phase 4]
A Phase 4 randomized, placebo-controlled crossover trial evaluated methylphenidate hydrochloride controlled release capsules in adults with …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-10-20FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII — Supplemental Application (Alvogen Inc.)
FDA approves Alvogen Inc.'s supplemental application to market generic mixed amphetamine salts tablets (dextroamphetamine/amphetamines) in m…
-
FDA approval · 2023-10-20FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals,Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for methylphenidate hydrochloride (generic). This approval supports the ava…
-
FDA approval · 2023-10-20FDA Approved: DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application from SpecGx LLC for a generic product containing dextroamphetamine saccharate and amphetamine aspart…
-
FDA approval · 2023-10-18FDA Approved: AMPHETAMINE SULFATE — Supplemental Application (Solco Healthcare US, LLC)
FDA approved a supplemental application for Amphetamine Sulfate from Solco Healthcare US, LLC.
-
FDA approval · 2023-10-18FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Supplemental Application (Rhodes Pharmaceuticals L.P.)
FDA approved a supplemental application for Rhodes Pharmaceuticals L.P. for a four-ingredient amphetamine product (dextroamphetamine sacchar…
-
FDA approval · 2023-10-17FDA Approved: AMPHETAMINE SULFATE — Supplemental Application (Granules Pharmaceuticals Inc.)
FDA approved a supplemental application for Amphetamine sulfate from Granules Pharmaceuticals Inc. to support a formulation change to a gran…
-
FDA approval · 2023-10-17FDA Approved: GUANFACINE — Original Application (Advagen Pharma Ltd)
FDA approves Advagen Pharma Ltd's generic guanfacine as an approved product under ANDA 216762, confirming it as a generic version of guanfac…
-
FDA approval · 2023-10-16FDA Approved: AMPHETAMINE SULFATE — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA approved a supplemental application for amphetamine sulfate (Amneal Pharmaceuticals NY LLC), resulting in an updated regulatory approval…
-
FDA approval · 2023-10-13FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application from Prasco Laboratories for a four-salt combination product containing dextroamphetamine saccharate…
-
FDA approval · 2023-10-13FDA Approved: APTENSIO XR — Supplemental Application (Rhodes Pharmaceuticals L.P.)
FDA approved a supplemental application for Aptensio XR (methylphenidate hydrochloride) from Rhodes Pharmaceuticals L.P., approving changes …
-
FDA approval · 2023-10-13FDA Approved: FOCALIN XR — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for FOCALIN XR (dexmethylphenidate hydrochloride) by Sandoz Inc.
-
FDA approval · 2023-10-13FDA Approved: METHYLIN — Supplemental Application (SHIONOGI INC.)
FDA approved a supplemental application for METHYLIN (methylphenidate hydrochloride) from Shionogi Inc., potentially updating the label or i…
-
FDA approval · 2023-10-13FDA Approved: METHYLPHENIDATE HYDROCHLORIDE CD — Supplemental Application (Lannett Company, Inc.)
FDA approves a supplemental application for methylphenidate hydrochloride CD from Lannett Company, Inc. under NDA 021259.
-
FDA approval · 2023-10-13FDA Approved: FOCALIN — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for FOCALIN (dexmethylphenidate hydrochloride) submitted by Sandoz Inc., adding to the product's…
-
FDA approval · 2023-10-13FDA Approved: METHYLPHENIDATE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for methylphenidate (Sandoz Inc) to update the product labeling under the NDA.
-
FDA approval · 2023-10-13FDA Approved: RITALIN — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for RITALIN (methylphenidate hydrochloride) from Novartis Pharmaceuticals Corporation.
-
FDA approval · 2023-10-13FDA Approved: VYVANSE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for Vyvanse (lisdexamfetamine dimesylate) submitted by Takeda Pharmaceuticals America, indicating an…
-
FDA approval · 2023-10-13FDA Approved: DEXTROAMPHETAMINE SULFATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva Pharmaceuticals USA, Inc.'s supplemental application for dextroamphetamine sulfate (generic).
-
FDA approval · 2023-10-13FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application by Teva for a four-salt amphetamine product consisting of dextroamphetamine saccharate, amphetamine …
-
FDA approval · 2023-10-13FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Epic Pharma, LLC)
FDA approves Epic Pharma, LLC's supplemental application for a generic product containing dextroamphetamine saccharate, amphetamine aspartat…